Relaxin Therapy for Atrial Fibrillation
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 208 participants.
Also called NCT07359872
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 208 participants
- Sponsor
- Deeptankar DeMazumder
- Registry
-
NCT07359872
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07359872. Randomized; quadruple masking; primary purpose treatment. Start 2027-01-01 (anticipated); primary completion 2030-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Relaxin Therapy for Atrial Fibrillation
- Acronym
- Relax-in-AF
- Condition
- Atrial Fibrillation (AF)
- Condition
- Arrhythmia
- Condition
- Oxidative Stress
- Condition
- Stroke
- Condition
- Major Cardiovascular Event
- Condition
- Heart Failure
- Condition
- Catheter Ablation
- Condition
- Ablation of Atrial Fibrillation
- Intervention (Drug)
- Relaxin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Deeptankar DeMazumder
- Collaborator
- Relaxera Pharmaceuticals
- Collaborator
- McGowan Institute for Regenerative Medicine, University of Pittsburgh
- Collaborator
- Relaxera Pharmazeutische Gesellschaft mbH & Co. KG
Record details
- Record id
cardio:ct-nct07359872- Content hash
df61e07c4c6448f75b6dbf0532db81f23a617984668bf267274b4d28fbce99da